Literature DB >> 9770534

Deficient DNA-ligase activity in the metabolic disease tyrosinemia type I.

M J Prieto-Alamo1, F Laval.   

Abstract

Hereditary tyrosinemia type I (HT1) is an autosomal recessive inborn error of metabolism caused by the deficiency of fumarylacetoacetate hydrolase, the last enzyme in the tyrosine catabolism pathway. This defect results in accumulation of succinylacetone (SA) that reacts with amino acids and proteins to form stable adducts via Schiff base formation, lysine being the most reactive amino acid. HT1 patients surviving beyond infancy are at considerable risk for the development of hepatocellular carcinoma, and a high level of chromosomal breakage is observed in HT1 cells, suggesting a defect in the processing of DNA. In this paper we show that the overall DNA-ligase activity is low in HT1 cells (about 20% of the normal value) and that Okazaki fragments are rejoined at a reduced rate compared with normal fibroblasts. No mutation was found by sequencing the ligase I cDNA from HT1 cells, and the level of expression of the ligase I mRNA was similar in normal and HT1 fibroblasts, suggesting the presence of a ligase inhibitor. SA was shown to inhibit in vitro the overall DNA-ligase activity present in normal cell extracts. The activity of purified T4 DNA-ligase, whose active site is also a lysine residue, was inhibited by SA in a dose-dependent manner. These results suggest that accumulation of SA reduces the overall ligase activity in HT1 cells and indicate that metabolism errors may play a role in regulating enzymatic activities involved in DNA replication and repair.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9770534      PMCID: PMC22879          DOI: 10.1073/pnas.95.21.12614

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  36 in total

1.  The occurrence of hepatoma in the chronic form of hereditary tyrosinemia.

Authors:  A G Weinberg; C E Mize; H G Worthen
Journal:  J Pediatr       Date:  1976-03       Impact factor: 4.406

2.  Hereditary tyrosinemia type I (chronic form): pathologic findings in the liver.

Authors:  L P Dehner; D C Snover; H L Sharp; N Ascher; R Nakhleh; D L Day
Journal:  Hum Pathol       Date:  1989-02       Impact factor: 3.466

3.  Chromosomal instability in hereditary tyrosinemia type I.

Authors:  E Gilbert-Barness; L A Barness; L F Meisner
Journal:  Pediatr Pathol       Date:  1990

Review 4.  Mammalian DNA ligases.

Authors:  A E Tomkinson; D S Levin
Journal:  Bioessays       Date:  1997-10       Impact factor: 4.345

5.  Hereditary tyrosinemia. Formation of succinylacetone-amino acid adducts.

Authors:  S Manabe; S Sassa; A Kappas
Journal:  J Exp Med       Date:  1985-09-01       Impact factor: 14.307

6.  Biochemical studies of a patient with hereditary hepatorenal tyrosinemia: evidence of glutathione deficiency.

Authors:  E Stoner; H Starkman; D Wellner; V P Wellner; S Sassa; A B Rifkind; A Grenier; P G Steinherz; A Meister; M I New
Journal:  Pediatr Res       Date:  1984-12       Impact factor: 3.756

7.  Multiple hypersensitivity to mutagens in a cell strain (46BR) derived from a patient with immuno-deficiencies.

Authors:  I A Teo; C F Arlett; S A Harcourt; A Priestley; B C Broughton
Journal:  Mutat Res       Date:  1983-02       Impact factor: 2.433

8.  Different molecular basis for fumarylacetoacetate hydrolase deficiency in the two clinical forms of hereditary tyrosinemia (type I).

Authors:  R M Tanguay; J P Valet; A Lescault; J L Duband; C Laberge; F Lettre; M Plante
Journal:  Am J Hum Genet       Date:  1990-08       Impact factor: 11.025

9.  Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease.

Authors:  J M Chirgwin; A E Przybyla; R J MacDonald; W J Rutter
Journal:  Biochemistry       Date:  1979-11-27       Impact factor: 3.162

10.  Isolation and structure of a cDNA expressing a mammalian 3-methyladenine-DNA glycosylase.

Authors:  T R O'Connor; F Laval
Journal:  EMBO J       Date:  1990-10       Impact factor: 11.598

View more
  6 in total

1.  Point mutation instability (PIN) mutator phenotype as model for true back mutations seen in hereditary tyrosinemia type 1 - a hypothesis.

Authors:  Etresia van Dyk; Pieter J Pretorius
Journal:  J Inherit Metab Dis       Date:  2011-10-15       Impact factor: 4.982

2.  Geographical and Ethnic Distribution of Mutations of the Fumarylacetoacetate Hydrolase Gene in Hereditary Tyrosinemia Type 1.

Authors:  Francesca Angileri; Anne Bergeron; Geneviève Morrow; Francine Lettre; George Gray; Tim Hutchin; Sarah Ball; Robert M Tanguay
Journal:  JIMD Rep       Date:  2015-02-15

3.  Clinical and ABCB11 profiles in Korean infants with progressive familial intrahepatic cholestasis.

Authors:  Ji Sook Park; Jae Sung Ko; Jeong Kee Seo; Jin Soo Moon; Sung Sup Park
Journal:  World J Gastroenterol       Date:  2016-05-28       Impact factor: 5.742

4.  Nitisinone in the treatment of hereditary tyrosinaemia type 1.

Authors:  Patrick J McKiernan
Journal:  Drugs       Date:  2006       Impact factor: 9.546

Review 5.  Liver tumors in children with metabolic disorders.

Authors:  Deborah A Schady; Angshumoy Roy; Milton J Finegold
Journal:  Transl Pediatr       Date:  2015-10

6.  Partial complementation of a DNA ligase I deficiency by DNA ligase III and its impact on cell survival and telomere stability in mammalian cells.

Authors:  Catherine Le Chalony; Françoise Hoffschir; Laurent R Gauthier; Julia Gross; Denis S Biard; François D Boussin; Vincent Pennaneach
Journal:  Cell Mol Life Sci       Date:  2012-03-30       Impact factor: 9.261

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.